215 related articles for article (PubMed ID: 10656396)
1. The American Brachytherapy Society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis.
Nag S; Bice W; DeWyngaert K; Prestidge B; Stock R; Yu Y
Int J Radiat Oncol Biol Phys; 2000 Jan; 46(1):221-30. PubMed ID: 10656396
[TBL] [Abstract][Full Text] [Related]
2. Correlation between real-time intraoperative and postoperative dosimetry and its implications on intraoperative planning.
Yan C; Huq MS; Heron DE; Beriwal S; Wynn RB
Brachytherapy; 2019; 18(3):338-347. PubMed ID: 30655047
[TBL] [Abstract][Full Text] [Related]
3. Prostate brachytherapy postimplant dosimetry: seed orientation and the impact of dosimetric anisotropy in stranded implants.
Chng N; Spadinger I; Rasoda R; Morris WJ; Salcudean S
Med Phys; 2012 Feb; 39(2):721-31. PubMed ID: 22320782
[TBL] [Abstract][Full Text] [Related]
4. Effect of prostate size and isotope selection on dosimetric quality following permanent seed implantation.
Merrick GS; Butler WM; Dorsey AT; Lief JH
Tech Urol; 2001 Sep; 7(3):233-40. PubMed ID: 11575521
[TBL] [Abstract][Full Text] [Related]
5. Potential role of various dosimetric quality indicators in prostate brachytherapy.
Merrick GS; Butler WM; Dorsey AT; Lief JH
Int J Radiat Oncol Biol Phys; 1999 Jun; 44(3):717-24. PubMed ID: 10348304
[TBL] [Abstract][Full Text] [Related]
6. Critical organ dosimetry in permanent seed prostate brachytherapy: defining the organs at risk.
Crook JM; Potters L; Stock RG; Zelefsky MJ
Brachytherapy; 2005; 4(3):186-94. PubMed ID: 16182218
[TBL] [Abstract][Full Text] [Related]
7. A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy.
Potters L; Cao Y; Calugaru E; Torre T; Fearn P; Wang XH
Int J Radiat Oncol Biol Phys; 2001 Jul; 50(3):605-14. PubMed ID: 11395226
[TBL] [Abstract][Full Text] [Related]
8. Is intraoperative nomogram-based overplanning of prostate implants necessary?
D'Souza WD; Lee HK; Palmer MB; Smith LG; Pollack A
Int J Radiat Oncol Biol Phys; 2003 Jun; 56(2):462-7. PubMed ID: 12738321
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity of clinically relevant dosimetric parameters to contouring uncertainty in postimplant dosimetry of low-dose-rate prostate permanent seed brachytherapy.
Mashouf S; Safigholi H; Merino T; Soliman A; Ravi A; Morton G; Song WY
Brachytherapy; 2016; 15(6):774-779. PubMed ID: 27720310
[TBL] [Abstract][Full Text] [Related]
10. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer.
Nag S; Beyer D; Friedland J; Grimm P; Nath R
Int J Radiat Oncol Biol Phys; 1999 Jul; 44(4):789-99. PubMed ID: 10386635
[TBL] [Abstract][Full Text] [Related]
11. Correlation between pre- and postimplant dosimetry for iodine-125 seed implants for localized prostate cancer.
Al-Qaisieh B; Witteveen T; Carey B; Henry A; Bottomley D; Smith J; Franks K; Bownes P
Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):626-30. PubMed ID: 19540077
[TBL] [Abstract][Full Text] [Related]
12. Interobserver variability of 3.0-tesla and 1.5-tesla magnetic resonance imaging/computed tomography fusion image-based post-implant dosimetry of prostate brachytherapy.
Watanabe K; Katayama N; Katsui K; Matsushita T; Takamoto A; Ihara H; Nasu Y; Takemoto M; Kuroda M; Kanazawa S
J Radiat Res; 2019 Jul; 60(4):483-489. PubMed ID: 31083713
[TBL] [Abstract][Full Text] [Related]
13. Impact of MRI-based postimplant dosimetric assessment in prostate brachytherapy using contrast-enhanced T1-weighted images.
Ohashi T; Momma T; Yamashita S; Nagatsuma K; Kanai K; Kitagawa K; Takahashi S; Hanada T; Yorozu A; Shigematsu N
Brachytherapy; 2012; 11(6):468-75. PubMed ID: 22330102
[TBL] [Abstract][Full Text] [Related]
14. Brachytherapy for prostate cancer: summary of American Brachytherapy Society recommendations.
Nag S
Semin Urol Oncol; 2000 May; 18(2):133-6. PubMed ID: 10875454
[TBL] [Abstract][Full Text] [Related]
15. Comparison of intraoperative dosimetric implant representation with postimplant dosimetry in patients receiving prostate brachytherapy.
Stone NN; Hong S; Lo YC; Howard V; Stock RG
Brachytherapy; 2003; 2(1):17-25. PubMed ID: 15062159
[TBL] [Abstract][Full Text] [Related]
16. T2*-weighted image/T2-weighted image fusion in postimplant dosimetry of prostate brachytherapy.
Katayama N; Takemoto M; Yoshio K; Katsui K; Uesugi T; Nasu Y; Matsushita T; Kaji M; Kumon H; Kanazawa S
J Radiat Res; 2011; 52(5):680-4. PubMed ID: 21857148
[TBL] [Abstract][Full Text] [Related]
17. Is there a role for postimplant dosimetry after real-time dynamic permanent prostate brachytherapy?
Potters L; Calugaru E; Jassal A; Presser J
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1014-9. PubMed ID: 16682144
[TBL] [Abstract][Full Text] [Related]
18. Prostate brachytherapy intraoperative dosimetry using a combination of radiographic seed localization with a C-arm and deformed ultrasound prostate contours.
Golshan M; Mahdavi SS; Samei G; Lobo J; Pickles T; James Morris W; Keyes M; Peacock M; Salcudean SE; Spadinger I
Brachytherapy; 2020; 19(5):589-598. PubMed ID: 32682777
[TBL] [Abstract][Full Text] [Related]
19. Postimplant dosimetry for (125)I prostate implants: definitions and factors affecting outcome.
Stock RG; Stone NN; Lo YC; Malhado N; Kao J; DeWyngaert JK
Int J Radiat Oncol Biol Phys; 2000 Oct; 48(3):899-906. PubMed ID: 11020588
[TBL] [Abstract][Full Text] [Related]
20. Quality indicators and technique for analyzing permanent I-125 prostate seed implants: seven years postimplant dosimetry evaluation.
Marcu LG; Lawson JM; Rutten T; Gowda R
Med Phys; 2012 Jul; 39(7):4123-31. PubMed ID: 22830745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
